Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report

Sano,Masayuki; Yamamoto,Shinya; Uehara,Sho; Yuasa,Takeshi; Masuda,Hitoshi; Fukui,Iwao; Yonese,Junji

doi:10.3892/mco.2016.946

September-2016 Volume 5 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2016 Volume 5 Issue 3

Full Size Image

Case Report Open Access

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report

Authors:
- Masayuki Sano
- Shinya Yamamoto
- Sho Uehara
- Takeshi Yuasa
- Hitoshi Masuda
- Iwao Fukui
- Junji Yonese
View Affiliations / Copyright

Affiliations: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan

Copyright: © Sano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 208-210
|
Published online on: July 1, 2016

https://doi.org/10.3892/mco.2016.946
Expand metrics +

Abstract

Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer treated with combined androgen blockade (CAB). AWS is generally defined as subjective and/or objective improvement following discontinuation of an antiandrogen. However, the duration of the AWS response is usually limited. In addition, a complete response is quite rare. We herein present the case of a patient who achieved complete response from AWS, with the duration of this response lasting for >6 years. A 72‑year‑old man with metastatic prostate cancer received CAB with a luteinizing hormone‑releasing hormone analog and bicalutamide. In addition, for local cancer control, external beam radiation therapy (70 Gy) to the prostate was performed. Subsequently, the serum prostate‑specific antigen (PSA) level reached a nadir (undetectable level). Four years later, the patient's serum PSA level started to rise, and bicalutamide was discontinued to confirm AWS at a serum PSA level of 0.34 ng/ml. The PSA level immediately decreased again to an undetectable level (0.00 ng/ml), where it has been remained for 6 years. Bone scintigraphy and computed tomography scans have shown no evidence of bone or other metastases since the introduction of AWS. To the best of our knowledge, there have been no reports of such a long duration of complete response from AWS. Therefore, this phenomenon should always be considered, even in patients with advanced disease.

View Figures

View References

1	Paul R and Breul J: Antiandrogen withdrawal syndrome associated with prostate cancer therapies: Incidence and clinical significance. Drug Saf. 23:381–390. 2000. View Article : Google Scholar : PubMed/NCBI
2	Kelly WK and Scher HI: Prostate-specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol. 149:607–609. 1993.PubMed/NCBI
3	Scher HI and Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 11:1566–1572. 1993.PubMed/NCBI
4	Small EJ and Carroll PR: Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology. 43:408–410. 1994. View Article : Google Scholar : PubMed/NCBI
5	Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, et al: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 180:921–927. 2008. View Article : Google Scholar : PubMed/NCBI
6	Noguchi K, Teranishi J, Uemura H, Fujikawa N, Saito K and Murai T: Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: Two case reports. Int J Urol. 13:1259–1261. 2006. View Article : Google Scholar : PubMed/NCBI
7	Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D and Crawford ED: Southwest Oncology Group: Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest oncology group trial (SWOG 9426). Cancer. 112:2393–2400. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M and Miyamoto M: Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63:149–153. 2003.PubMed/NCBI
9	Takeshita H, Kawakami S and Fukui I: Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy. Int J Urol. 16:337–338. 2009. View Article : Google Scholar : PubMed/NCBI
10	Culp SH, Schelhammer PF and Williams MB: Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEED-based study. Eur Urol. 65:1058–1066. 2014. View Article : Google Scholar : PubMed/NCBI
11	Small EJ and Srinivas S: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patience with advanced prostate cancer. Cancer. 76:1428–1434. 1995. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report

This article is mentioned in:

Abstract

Figure 1

Related Articles